This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-01. Anything still debated is marked as such rather than presented as settled.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
=== System II === Cytochromes c in chloroplasts, Gram-positive bacteria, cyanobacteria, and some Pseudomonadota are produced by the cytochrome c synthesis (ccs) system. It is composed of two membrane proteins CcsB and CcsA. The CcsBA protein complex was suggested to act as a heme transporter during the attachment process. In some organisms such as Helicobacter hepaticus both proteins are found as a fused single protein. Apoprotein transport occurs via the Sec translocon as well.
Food and Drug Administration (FDA) on 24 July 2015, and evolocumab (Repatha, Amgen), approved on 27 August 2015; both were also authorised in the European Union in 2015. Inclisiran (Leqvio, Novartis), a small interfering RNA (siRNA) that reduces PCSK9 production in the liver and is administered by twice-yearly injection, was subsequently approved by the European Medicines Agency in December 2020 and by the FDA in December 2021. PCSK9 inhibitors have been shown to significantly reduce LDL-C levels and increase HDL-C levels significantly. They were found to lower the incidence of myocardial infarction and stroke in individuals at high cardiovascular risk (over 15% using PREDICT cardiovascular disease calculator), such as those with at least five risk factors, established cardiovascular disease, or hereditary lipid disorders without cardiovascular risk factor, but not in those at low to moderate risk. A 2023 meta-analysis has indicated that alirocumab may reduce all-cause mortality, whereas evolocumab has no significant effect on all-cause mortality. The efficacy of bococizumab remains unclear, as its development was discontinued by Pfizer in 2016. The most recent guidelines for cholesterol management from the American Heart Association and American College of Cardiology now provide guidance for when PCSK9 inhibitors should be considered, particularly focusing on cases in which maximally tolerated statin and ezetimibe fail to achieve goal LDL reduction. A possible side effect of the monoclonal antibody might be irritation at the injection site.
Ribulose-1,5-bisphosphate carboxylase/oxygenase, commonly known by the abbreviations RuBisCo, rubisco, RuBPCase, or RuBPco, is an enzyme (EC 4.1.1.39) involved in the light-independent (or "dark") part of photosynthesis, including the carbon fixation by which atmospheric carbon dioxide is converted by plants and other photosynthetic organisms to energy-rich molecules such as glucose. It emerged approximately four billion years ago in primordial metabolism prior to the presence of oxygen on Earth. It is the most abundant enzyme on Earth. In chemical terms, it catalyzes the carboxylation of ribulose-1,5-bisphosphate (also known as RuBP).
=== 30 December === The Ukrainian army claimed to have shot down 16 drones launched by Russian forces at Kyiv and other cities. The Mayor of Kyiv, Vitali Klitschko, stated that two were shot down outside Kyiv while five were shot down "over" Kyiv. President Putin and Chinese President Xi Jinping held talks via video link in which the latter reassured the former that he would maintain an "objective and fair stance" regarding the situation, according to CCTV.
==== Client interactions ==== When acting as clients, blue tangs normally approach cleaning stations inhabited by cleaner gobies. Cleaners must be careful because the spine on both sides of the caudal peduncle are sharp and can inflict painful wounds. When in the client role, blue tangs will pose as they enter the cleaning station. Posing occurs before the cleaners inspect the incoming client fish. Fish who pose while in cleaning stations have a higher chance of getting cleaned. Blue tangs almost exclusively pose through head stands.
Sources: en.wikipedia.org
=== Mbizo Cricket Centre === The largest venture by the Mid West Rhinos is the ongoing Mbizo Cricket centre project. Aimed at developing cricket in the underprivileged high density suburb of Mbizo, the cricket centre was part funded by the Australian Embassy and Indian auto mobile manufacturer Mahindra. The project has been vital in increasing awareness and knowledge of cricket in the area and has resulted in producing a number of decent cricketers. The project stalled in 2014 but in 2015, the Australian Embassy and prominent businessmen John and Charles Gardiner of the Cold Chain Group provided funds to complement the existing facilities with a large pavilion. Still under construction, the pavilion will include changing rooms, kitchen, running water, electricity and meeting areas. Whilst the project was slow to gain ground, the support from the local community was immense. When club cricket was played at the centre it would not be unusual to see 60 players arriving on match day vying for a place on the team. Many of the cricketers who played for Mbizo have gone on to represent other local league teams and some have even appeared for the Rhinos.
According to the 2022 census, Belize's population is 397,483. Belize's total fertility rate in 2023 was 2.010 children per woman. Its birth rate was 17.8 births/1,000 population (2022), and the death rate was 6.3 deaths/1,000 population (2022). A substantial ethnic-demographic shift has been occurring since 1980 when the Creoles, formerly a majority of the population, have become outnumbered by the Hispanic/Mestizo community due to many Creoles moving to the United States, as well as a rising Mestizo birth rate and migration from Latin America.
=== Antibacterial immune factor === Researchers have isolated a powerful antibacterial peptide, VK25, from the blood plasma of Komodo dragons. Based on their analysis of this peptide, they have synthesized a short peptide dubbed DRGN-1 and tested it against multidrug-resistant (MDR) pathogens. Preliminary results of these tests show that DRGN-1 is effective in killing drug-resistant bacterial strains and even some fungi. It has the added observed benefit of significantly promoting wound healing in both uninfected and mixed biofilm infected wounds.
=== Economic solar panel === The MAXXUN project was to develop a system of disruptive solar cells based on the luminescent solar concentrating (LSC) technology, in order to lower the investment for a solar energy system by more than half. Altran Technologies consultants have worked during a year with the award-winning team to increase the surface area of the panel from 2.5 cm2 to 10 cm2; to apply an absorbing and dispersing layer on this extra surface area; to optimize light power under different conditions; to build a demonstration model and to identify potential partners.
Sources: en.wikipedia.org
== Biological function == Flavin reductases exist in a variety of organisms, including animals and bacteria. In luminous organisms, flavin reductase is important in the luciferase process. In an experiment with P. fischeri and B. harveyi cells, bioluminescence was increased as the in vivo concentration of flavin reductase was increased. This suggests a connection between either a flavin reductase-luciferase complex or reduced flavin and the luminescence process in bacteria. The bacteria oxidize the reduced flavin mononucleotide to oxidized FMN and transfer it through free fusion to generate light. In humans, flavin reductase often catalyzes an NADPH dependent reduction of flavin mononucleotide which occurs in methemoglobin in erythrocytes and the liver. It has also been suggested that flavin reductases play a role in the production of hydrogen peroxide. This would be biologically helpful as H2O2 assists the body in maintaining homeostatic microbiota. A study showed that women with lactobacillus that produced hydrogen peroxide were less likely to develop bacterial vaginosis prebirth. It was also seen in Trichomonas vaginalis that decreased levels of flavin reductase increased the cycling of metronidazole because flavin reductase has an antioxidative effect, which decreases oxygen levels, maintaining the metronidazole population.
Surveys by Gallup, the National Opinion Research Centre and the Pew Organisation conclude that spiritually committed people are twice as likely to report being "very happy" than the least religiously committed people. An analysis of over 200 social studies contends that "high religiousness predicts a lower risk of depression and drug abuse and fewer suicide attempts, and more reports of satisfaction with sex life and a sense of well-being. However, the links between religion and happiness are always very broad in nature, highly reliant on scripture and small sample number. To that extent, there is a much larger connection between religion and suffering (Lincoln 1034)." And a review of 498 studies published in peer-reviewed journals concluded that a large majority of them showed a positive correlation between religious commitment and higher levels of perceived well-being and self-esteem and lower levels of hypertension, depression, and clinical delinquency. A meta-analysis of 34 recent studies published between 1990 and 2001 found that religiosity has a salutary relationship with psychological adjustment, being related to less psychological distress, more life satisfaction, and better self-actualization.
Venoms of centipedes remained largely unstudied, and the components remain largely unknown. The venom of the Chinese red-headed centipede contains a small peptide toxin called RhTx, which increases activation of the TRPV1 ion channel, causing a localized burning pain. The crude venom is said to be toxic in mice and to induce platelet aggregation. In addition, another 26 neurotoxins belonging to 10 different groups of peptides have been identified. In January 2018, Chinese scientists found an antidote to the painful venom of centipede in the drug retigabine, used to treat epilepsy. The biological actions of the toxins in centipede venom are mostly unknown. A peptide named S. mutilans venom toxin peptide (SsmTP) and S. mutilans 6 were identified in S. mutilans's venom. SsmTP consists of 66 amino acids, and its composition highly resembles those of neurotoxins. The peptide is found within the venom duct. SsmTP was found to be toxic to cells depending on the concentration administered. It promotes cell growth in low concentrations in vitro (i.e. outside a living organism), but is cytotoxic in high concentrations. A low concentration of SsmTP also protects cells from oxidative damage by inhibiting programmed cell death (apoptosis) and the inflammatory response initiator caspase-1.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.